ES2067068T3 - Composiciones terapeuticas con liberacion controlada de medicamentos soportados en polimeros reticulados y recubiertos con peliculas polimericas y sus procesos de preparacion. - Google Patents

Composiciones terapeuticas con liberacion controlada de medicamentos soportados en polimeros reticulados y recubiertos con peliculas polimericas y sus procesos de preparacion.

Info

Publication number
ES2067068T3
ES2067068T3 ES91103224T ES91103224T ES2067068T3 ES 2067068 T3 ES2067068 T3 ES 2067068T3 ES 91103224 T ES91103224 T ES 91103224T ES 91103224 T ES91103224 T ES 91103224T ES 2067068 T3 ES2067068 T3 ES 2067068T3
Authority
ES
Spain
Prior art keywords
coated
controlled release
medicines
supported
therapeutic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91103224T
Other languages
English (en)
Inventor
Fabio Carli
Italo Colombo
Leonardo Rabaglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectorpharma International SpA
Original Assignee
Vectorpharma International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectorpharma International SpA filed Critical Vectorpharma International SpA
Application granted granted Critical
Publication of ES2067068T3 publication Critical patent/ES2067068T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)

Abstract

LOS COMPUESTOS TERAPEUTICOS DESCRITOS CON LIBERACION CONTROLADA DE MEDICAMENTOS COMPRENDEN UN MEDICAMENTO CARGADO SOBRE PARTICULAS DE UN POLIMERO NO IONICO ENLAZADO INSOLUBLE PERO HINCHABLE EN AGUA, USANDO TANTO METODOS DE HINCHADO CON SOLUCIONES DEL MEDICAMENTO O METODOS DE CO-DESMENUZAMIENTO A ALTA ENERGIA. LAS PARTICULAS DEL MEDICAMENTO CARGADO SE RECUBREN CON UNA PELICULA DE POLIMEROS CAPAZ DE CONTROLAR LA LIBERACION DEL MEDICAMENTO, PARA OBTENER UNA LIBERACION PROLONGADA DEL MEDICAMENTO (INCLUSO EXCEDE DE 24 HORAS) MIENTRAS TIENE UNA ALTA BIOACTIVIDAD.
ES91103224T 1990-03-06 1991-03-04 Composiciones terapeuticas con liberacion controlada de medicamentos soportados en polimeros reticulados y recubiertos con peliculas polimericas y sus procesos de preparacion. Expired - Lifetime ES2067068T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT19571A IT1241417B (it) 1990-03-06 1990-03-06 Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Publications (1)

Publication Number Publication Date
ES2067068T3 true ES2067068T3 (es) 1995-03-16

Family

ID=11159155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91103224T Expired - Lifetime ES2067068T3 (es) 1990-03-06 1991-03-04 Composiciones terapeuticas con liberacion controlada de medicamentos soportados en polimeros reticulados y recubiertos con peliculas polimericas y sus procesos de preparacion.

Country Status (13)

Country Link
US (1) US5275824A (es)
EP (1) EP0446753B1 (es)
JP (1) JP3240387B2 (es)
KR (1) KR0175935B1 (es)
AT (1) ATE114242T1 (es)
CA (1) CA2037410C (es)
DE (1) DE69105222T2 (es)
ES (1) ES2067068T3 (es)
HU (1) HUT59588A (es)
IT (1) IT1241417B (es)
PL (1) PL289322A1 (es)
RU (1) RU2067859C1 (es)
YU (1) YU34491A (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
GB2258613B (en) * 1991-08-12 1996-01-10 Euro Celtique Sa Pharmaceutical diltiazem formulation
IT1252867B (it) * 1991-12-31 1995-06-28 Gentili Ist Spa Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
ATE137668T1 (de) * 1992-07-24 1996-05-15 Labopharm Inc Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung
DE4236090C1 (de) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmazeutische Zubereitung für die Fluoridionen-Versorgung
ZA941544B (en) * 1993-03-05 1994-10-31 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same.
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
FR2711804B1 (fr) * 1993-10-22 1996-01-19 Pf Medicament Procédé de contrôle de la dissolution de formes galéniques à libération modifiée à l'aide d'un réactif solide et sachet dose contenant un tel réactif.
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
AT403988B (de) * 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
EP0714411B1 (en) * 1994-06-16 1999-07-21 PHARMACIA & UPJOHN S.p.A. Process for obtaining mucoadhesive starch
RU2142791C1 (ru) * 1994-08-09 1999-12-20 Крка, Товарна Здравил, П.О. Твердая лекарственная форма, способная к стабильному выделению активного вещества альпразолама, и способ ее получения
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
AU4844796A (en) * 1995-03-02 1996-09-18 Takeda Chemical Industries Ltd. A prolonged release composition, use and production thereof
JP3471977B2 (ja) * 1995-06-02 2003-12-02 信越化学工業株式会社 液体状可塑剤を用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
EP0761209A3 (en) * 1995-09-01 1998-02-04 J.B. Chemicals & Pharmaceuticals Ltd. Controlled release formulations of ranitidine
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
IT1282381B1 (it) * 1996-04-29 1998-03-20 Trans Bussan S A Nuove formulazioni di diacereina, ottenute per inclusione del principio attivo in idrogel polisaccaridi
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6096834A (en) * 1997-04-04 2000-08-01 Monsanto Company Hydrolyzable delivery system using crosslinked polymeric resins as vehicles
US6890524B1 (en) 1997-04-04 2005-05-10 Monsanto Company Hydrolyzable delivery system using cross-linked polymeric resins as vehicles
WO1998044952A1 (en) 1997-04-04 1998-10-15 Monsanto Company pH-SELECTIVE DELIVERY SYSTEM USING CROSS-LINKED POLYMERIC RESINS AS VEHICLES
FR2766709B1 (fr) * 1997-07-31 2000-04-07 Dominique Cingotti Procede pour la preparation d'un extrait de principes actifs sous forme de microgranules a base de fibres alimentaires entierement solubles destines a differentes formes galeniques
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
FR2792528A1 (fr) * 1999-04-22 2000-10-27 Ethypharm Lab Prod Ethiques Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
WO2000071098A1 (en) * 1999-05-24 2000-11-30 Purepac Pharmaceutical Co. A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
IL150053A0 (en) * 1999-12-06 2002-12-01 Mendell Co Inc Edward Pharmaceutical superdisintegrant
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
AP1748A (en) * 2001-03-13 2007-06-11 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
RU2191577C1 (ru) * 2001-04-19 2002-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая противовоспалительная композиция и способ ее получения
KR20010069756A (ko) * 2001-05-08 2001-07-25 유형선 소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE60205491T2 (de) * 2001-06-29 2006-06-01 Eurand Pharmaceuticals Ltd. Verfahren zur arzneimittelaktivierung mittels schwingmühle
DE60223382T2 (de) * 2001-06-29 2008-09-11 Eurand Pharmaceuticals Ltd., Bray Verfahren für die thermodynamische aktivierung von wasserlöslichen arzneimitteln, die in vernetzten polymeren geladen sind
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
JP3966459B2 (ja) 2002-05-23 2007-08-29 株式会社日立製作所 ストレージ機器管理方法、システム、およびプログラム
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
DE10247037A1 (de) 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
RU2286779C2 (ru) * 2003-02-06 2006-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая диуретическим и антигипертензивным действием, и способ ее изготовления
UA80872C2 (uk) * 2003-03-31 2007-11-12 Пліва-Лахема А.С. Фармацевтична композиція, що містить як активну речовину платиновий комплекс, і спосіб її виготовлення
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
RU2380092C2 (ru) * 2004-01-30 2010-01-27 Кориум Интернэшнл, Инк. Быстро растворяющаяся пленка для доставки активного агента
US20070224281A1 (en) * 2004-07-22 2007-09-27 Amorepacific Corporation Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
WO2007096902A2 (en) * 2006-02-23 2007-08-30 Lupin Limited Solid oral dosage forms of griseofulvin
CN101410123A (zh) 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的双氯芬酸和β－环糊精的制剂
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
CA2749074A1 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
AU2008261957A1 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
BRPI0812966A2 (pt) * 2007-06-25 2017-05-16 Encysive Pharmaceuticals Inc formulações de n-(2-acetil-4,6-dimetilfenil)-3-{[(3,4 dimetil-5-isoxazolil)amino]sulfonil}-2-tiofenocarboxamida
US20090024570A1 (en) * 2007-07-20 2009-01-22 Oracle Internatonal Corporation User defined query rewrite mechanism
ES2560899T3 (es) 2007-09-14 2016-02-23 Wockhardt Limited Composiciones de diacereína
US20100285114A1 (en) * 2007-09-27 2010-11-11 Rahul Dabre Pharmaceutical compositions of rhein or diacerein
AU2013200968B2 (en) * 2007-09-27 2013-11-21 Wockhardt Limited Pharmaceutical compositions of rhein or diacerein
ES2392781T3 (es) 2007-09-27 2012-12-13 Wockhardt Limited Composiciones farmacéuticas de reína o diacereína
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
EP2389168A2 (en) * 2009-01-22 2011-11-30 USV Limited Pharmaceutical compositions comprising phosphate-binding polymer
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
IE20100799A1 (en) 2010-12-22 2012-08-01 Eurand Pharmaceuticals Ltd Pharmaceutical composites of poorly water soluble drugs and polymers
KR20120135063A (ko) * 2011-06-01 2012-12-12 닛토덴코 가부시키가이샤 입자 제제 및 그 제조 방법
US9452107B2 (en) * 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
JP2019505535A (ja) * 2016-02-05 2019-02-28 エントレガ，インコーポレイテッド 活性剤の送達のための乾燥剤を含む経口製剤
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1218102A (en) 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
DE2643004A1 (de) 1975-09-25 1977-06-16 Mitchell Beazley Encyclopedias Audiovisuelles informationssystem - system zum anordnen und wiederauffinden von informationen
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
HU189534B (en) 1981-09-09 1986-07-28 Chinoin Rt.,Hu Process for producing new tablets containing cyclodextrin polymer as desintegrator
EP0078430B2 (de) 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
EP0147780A3 (en) 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
CA1236023A (en) 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
ES2022454B3 (es) * 1986-06-17 1991-12-01 Recordati Ind Chimica E Farm S P A Sistema terapeutico para la liberacion controlada de drogas.
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4894239A (en) 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US4795644A (en) 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
IE63242B1 (en) * 1988-06-24 1995-04-05 Abbott Lab Pharmaceutical granules and tablets made therefrom

Also Published As

Publication number Publication date
JPH0769927A (ja) 1995-03-14
IT9019571A1 (it) 1991-09-06
JP3240387B2 (ja) 2001-12-17
IT9019571A0 (it) 1990-03-06
EP0446753A1 (en) 1991-09-18
DE69105222T2 (de) 1995-04-06
EP0446753B1 (en) 1994-11-23
CA2037410A1 (en) 1991-09-07
DE69105222D1 (de) 1995-01-05
HUT59588A (en) 1992-06-29
IT1241417B (it) 1994-01-14
YU34491A (sh) 1994-06-10
US5275824A (en) 1994-01-04
CA2037410C (en) 2001-09-04
HU910707D0 (en) 1991-09-30
PL289322A1 (en) 1992-05-04
KR910016320A (ko) 1991-11-05
ATE114242T1 (de) 1994-12-15
KR0175935B1 (ko) 1999-03-20
RU2067859C1 (ru) 1996-10-20

Similar Documents

Publication Publication Date Title
ES2067068T3 (es) Composiciones terapeuticas con liberacion controlada de medicamentos soportados en polimeros reticulados y recubiertos con peliculas polimericas y sus procesos de preparacion.
US3641237A (en) Zero order release constant elution rate drug dosage
ES8604020A1 (es) Un procedimiento para la obtencion de polimeros porosos reticulados para liberacion controlada de farmacos
ATE251641T1 (de) Pharmazeutische zusammensetzungen mit kontinuierlicher abgabe, die mit wasserlöslichen polymeren kovalent gebundene polypeptide enthalten
FI961996A0 (fi) Pitkitetysti vapauttavat valmisteet metoprololin 24 tunnin pituiseksi vapauttamiseksi
AU4113093A (en) Bioadhesive microspheres and their use as drug delivery and imaging systems
ATE153538T1 (de) Transdermale therapeutische zubereitungen
ES2093097T3 (es) Formulacion de farmacos de cesion controlada.
ES2001897A6 (es) Procedimiento para la fabricacion de una tableta de liberacion controlada
ATE131039T1 (de) Arzneimittel in gelform in einem spender.
NO872381D0 (no) Fremgangsmaate for fremstilling av langsomt frigivende preparater.
DE69101710D1 (de) Arzneimittel freisetzendes polymeres system.
DK1125577T3 (da) Væskeformige medikamentindföringspræparater
ES2091363T3 (es) Compuesto farmaceutico de liberacion controlada con propiedades bioadhesivas.
ES2173891T3 (es) Sistema de liberacion pulsatil de un farmaco multiparticulado.
LU91325I2 (fr) Luminity (produit médical)le produit est microsphères lipidiques contenant du perflutren
ATE69725T1 (de) Pharmazeutische zubereitungen von acrivastine.
DK0421541T3 (da) Tabletstruktur, som kan deles
ATE178787T1 (de) Arznei zusammensetzungen, die ein arzneimittel, ein quervernetztes polymer, ein öl, und ein grenzflächenaktives mittel enthalten
ATE23266T1 (de) Pharmazeutische produkte in formen mit verzoegerter abgabe und verfahren an deren herstellung.
ES2060715T3 (es) Medicamentos escasamente solubles inmovilizados en substancias polimericas de una manera adecuada para incrementar su grado de disolucion.
SE8803822D0 (sv) Novel dosage form
IT1254898B (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
Passl Synthetic polymers in modern pharmacy

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 446753

Country of ref document: ES